Passage Bio Inc. (PASG)
NASDAQ: PASG
· Real-Time Price · USD
0.35
0.02 (7.36%)
At close: May 01, 2025, 3:58 PM
0.33
-5.35%
After-hours: May 01, 2025, 06:44 PM EDT
7.36% (1D)
| Bid | 0.31 |
| Market Cap | 21.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.77M |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | -0.43 |
| Analyst | Buy |
| Ask | 0.38 |
| Volume | 458,631 |
| Avg. Volume (20D) | 171,439 |
| Open | 0.33 |
| Previous Close | 0.33 |
| Day's Range | 0.32 - 0.38 |
| 52-Week Range | 0.30 - 1.64 |
| Beta | 1.59 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 60
Stock Exchange NASDAQ
Ticker Symbol PASG
Website https://www.passagebio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PASG stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1616.25% from the latest price.
Stock Forecasts6 months ago
+11.4%
Passage Bio shares are trading higher after the co...
Unlock content with
Pro Subscription
